找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Drug Discovery and Drug Development; The Indian Narrative Madhu Dikshit Book 2021 Springer Nature Singapore Pte Ltd. 2021 drug formulation.

[復(fù)制鏈接]
樓主: Malinger
21#
發(fā)表于 2025-3-25 05:56:35 | 只看該作者
22#
發(fā)表于 2025-3-25 07:59:07 | 只看該作者
,Regulatory Requirements and Quality Standards in India’s Clinical Trials Journey,e, transparent, and effective regulations for CTs to enable faster accessibility of new drug molecules in the country. The New Drugs and Clinical Trials Rules 2019 is a step in that direction. This chapter attempts to give an overview of the regulatory developments in the context of changed scenario
23#
發(fā)表于 2025-3-25 12:12:28 | 只看該作者
24#
發(fā)表于 2025-3-25 18:21:30 | 只看該作者
rch (NDDR) journey to date. Gathering contributions from prominent researchers in the Indian Pharma Industry and Academia, this book highlights their efforts, achievements, and the status quo of Indian NDDR.??.978-981-15-8004-8978-981-15-8002-4
25#
發(fā)表于 2025-3-25 22:48:45 | 只看該作者
https://doi.org/10.1007/978-3-7908-2367-7vel class antibiotic mersacidin and phase 3 clinical stage/regulatory approval of Orchid’s OCID 5090, and Wockhardt’s levonadifloxacin, alalevonadifloxacin, nafithromycin, and zidebactam are discussed.
26#
發(fā)表于 2025-3-26 01:14:56 | 只看該作者
Network Economics in Software Marketsse in India by 2017; however, until date, target could not be achieved. This underscores the need for development of new antileishmanial agent that is administered orally. Research efforts to identify new chemical entities, using both phenotypic and target-based screening led to the identification o
27#
發(fā)表于 2025-3-26 05:19:01 | 只看該作者
28#
發(fā)表于 2025-3-26 09:52:09 | 只看該作者
29#
發(fā)表于 2025-3-26 15:12:15 | 只看該作者
30#
發(fā)表于 2025-3-26 18:36:13 | 只看該作者
Traditional Medical System (TMS) for Sustainable Healthcare in India,ealth care system. As per WHO recommendation, TM should be a part of health and wellness and promote safe and effective use. It can be done by proper regulation, research and integrate products, practitioners and practice into TM health systems. This can be assigned that the sum total of the knowled
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-5 17:06
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
吴川市| 松江区| 阜平县| 长治市| 安塞县| 杭锦后旗| 郸城县| 合水县| 孟连| 盐边县| 嘉鱼县| 石首市| 鹤岗市| 乌海市| 郴州市| 汉沽区| 太康县| 元阳县| 社旗县| 哈巴河县| 梅州市| 金门县| 会东县| 嫩江县| 呈贡县| 临武县| 十堰市| 南漳县| 博野县| 沁水县| 邹平县| 永德县| 葵青区| 霍林郭勒市| 岚皋县| 静海县| 合川市| 镇雄县| 景洪市| 中牟县| 万宁市|